Diagnostic and management strategies for chronic hepatitis E infection. Issue 2 (1st February 2023)

• Record Type: Journal Article
• Authors: Abravanel, Florence; Lhomme, Sébastien; Marion, Olivier; Péron, Jean Marie; Kamar, Nassim; Izopet, Jacques
• Is Part Of: Expert review of anti-infective therapy. Volume 21:Issue 2(2023)
• Page Start: 143
• Page End: 148
• Publication Date: 2023-02-01
• Subjects: Hepatitis E virus -- hematological malignancies -- ribavirin -- solid organ transplant recipients -- zoonotic infection; Anti-infective agents -- Research -- Periodicals; 616.90461
• DOI: 10.1080/14787210.2023.2166932
• Languages: English
• ISSNs: 1478-7210

Abstract

ABSTRACT: Introduction: Hepatitis E Virus (HEV) was initially thought to cause only acute infections, but the discovery of chronic hepatitis E in immunocompromised patients has profoundly changed our understanding of the virus. Areas covered: We describe the physiopathology, diagnosis, and clinical management of chronic HEV infection. The virus can persist in nearly two-thirds of immunosuppressed patients. Reducing immunosuppression is the first immunomodulatory strategy to cure chronic hepatitis E. But this may not always be feasible or effective. Ribavirin monotherapy for 3 months has been recommended as first-line treatment for chronically infected patients. Ribavirin is around 80% effective at eradicating HEV in retrospective studies. Apart from ribavirin, interferon has been successfully used in liver transplants recipients, but if the patient does not respond, no other alternative drug is available. The vaccine available to prevent HEV infection is one available only in China. Expert opinion: HEV infection is a major concern in immunocompromised patients. But the therapeutic arsenal is limited to ribavirin and interferon. Both produce several side effects and new drugs are urgently needed. Moreover, preventive strategies to limit HEV transmission and/or evolution to a chronic infection are also required.